MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: An ISG/GEIS study

Molecular Cancer Therapeutics

Volumn 13, Issue 1, 2013, Pages 249-259

  Martin Broto, Javier ^a   Gutierrez, Antonio M ^a   Ramos, Rafael F ^a   Lopez Guerrero, José A ^b   Ferrari, Stefano ^c   Stacchiotti, Silvia ^d   Picci, Piero ^c   Calabuig, Silvia ^a   Collini, Paola ^e   Gambarotti, Marco ^c   Bague, Silvia ^f   Dei Tos, Angelo P ^g   Palassini, Elena ^d   Luna, Pablo ^a   Cruz, Josefina ^h   Cubedo, Ricardo ⁱ   Martinez Trufero, Javier ^j   Poveda, Andres ^k   Casali, Paolo G ^d   Fernandez Serra, Antonio ^b   Lopez Pousa, Antonio ^l   Gronchi, Alessandro ^e   more..

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^c RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^d Adult Mesenchymal Tumor   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f HOSPITAL SANT PAU   (Spain)

^g General Hospital of Treviso   (Italy)

^h HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

ⁱ HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^j HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^k IVO   (Spain)

^l Sant Pau University Hospital   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN; GLUTATHIONE TRANSFERASE A1; IFOSFAMIDE; MESSENGER RNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIMB SOFT TISSUE SARCOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TRUNK WALL SOFT TISSUE SARCOMA; TUMOR BIOPSY; UNDIFFERENTIATED PLEOMORPHIC SARCOMA;

AGED; ANTHRACYCLINES; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, MULTIPLE; EXTREMITIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM RECURRENCE, LOCAL; P-GLYCOPROTEIN; PROGNOSIS; SARCOMA;

EID: 84892608351     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0406     Document Type: Article

References (44)

1. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23 Suppl 7: vii92-9.
2. Reichardt P, Tilgner J, Hohenberger P, Dorken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 1998;16: 1438-43.
3. Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer HJ, Van Hoesel Q, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000; 18:2676-84.
4. Santoro A. Advanced soft tissue sarcoma: how many more trials with anthracyclines and ifosfamide? Ann Oncol 1999;10:151-4.
5. Munoz M, Henderson M, Haber M, Norris M. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life 2007; 59:752-7.
6. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-302.
7. Altenberg GA. Structure of multidrug-resistance proteins of the ATPbinding cassette (ABC) superfamily. Curr Med Chem Anticancer Agents 2004;4:53-62.
8. Grant CE, Gao M, DeGorter MK, Cole SP, Deeley RG. Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos 2008;36:2571-81.
9. Lo HW, Ali-Osman F. Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Curr Opin Pharmacol 2007;7:367-74.
10. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995;30:445-600.
11. Jimenez RE, Zalupski MM, Frank JJ, Du W, Ryan JR, Lucas DR. Multidrug resistance phenotype in high grade soft tissue sarcoma: correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy. Cancer 1999;86:976-81.
12. Komdeur R, Plaat BE, van der Graaf WT, Hoekstra HJ, Hollema H, van den Berg E, et al. Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade. Eur J Cancer 2003;39:909-16.
13. Oda Y, Saito T, Tateishi N, Ohishi Y, Tamiya S, Yamamoto H, et al. ATPbinding cassette superfamily transporter gene expression in human soft tissue sarcomas. Int J Cancer 2005;114:854-62.
14. Serra M, Scotlandi K, Reverter-Branchat G, Ferrari S, Manara MC, Benini S, et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol 2003;21:536-42.
15. Serra M, Pasello M, Manara MC, Scotlandi K, Ferrari S, Bertoni F, et al. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. Int J Oncol 2006;29:1459-68.
16. Citti A, Boldrini R, Inserra A, Alisi A, Pessolano R, Mastronuzzi A, et al. Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy. Int J Oncol 2012;41:117-24.
17. Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol 2012;30:850-6.
18. Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 22DDCT Method. Methods 2001;25:402-8.
19. Haimeur A, Conseil G, Deeley RG, Cole SP. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 2004;5:21-53.
20. Mulders TM, Keizer, Ouwerkerk J, van der Velde EA, Breimer DD, Mulder GJ. Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers. Clin Cancer Res 1995;1:1525-36.
21. Cole SP, Deeley RG. Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol Sci 2006;27:438-46.
22. Hipfner DR, Deeley RG, Cole SP. Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1999;1461:359-76.
23. Li XQ, Li J, Shi SB, Chen P, Yu LC, Bao QL. Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy. Int J Biol Markers 2009;24:230-7.
24. Ota E, Abe Y, Oshika Y, Ozeki Y, Iwasaki M, Inoue H, et al. Expression of the multidrug resistance-associated protein (MRP) gene in non-smallcell lung cancer. Br J Cancer 1995;72:550-4.
25. Li J, Li ZN, Yu LC, Bao QL, Wu JR, Shi SB, et al. Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. Lung Cancer 2010;69:116-22.
26. Nooter K, Brutel de la Riviere G, Look MP, van Wingerden KE, Henzen-Logmans SC, Scheper RJ, et al. The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer 1997;76:486-93.
27. Moureau-Zabotto L, Ricci S, Lefranc JP, Coulet F, Genestie C, Antoine M, et al. Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. Br J Cancer 2006;94:473-80.
28. Nakanishi H, Myoui A, Ochi T, Aozasa K. P-glycoprotein expression in soft-tissue sarcomas. J Cancer Res Clin Oncol 1997;123: 352-6.
29. Oda Y, Ohishi Y, Saito T, Hinoshita E, Uchiumi T, Kinukawa N, et al. Nuclear expression of Y-box-binding protein-1 correlates with Pglycoprotein and topoisomerase IIa expression, and with poor prognosis in synovial sarcoma. J Pathol 2003;199:251-8.
30. Coley HM, Verrill MW, Gregson SE, Odell DE, Fisher C, Judson IR. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma. Eur J Cancer 2000;36:881-8.
31. Engellau J, Bendahl PO, Persson A, Domanski HA, Akerman M, Gustafson P, et al. Improved prognostication in soft tissue sarcoma: independent information from vascular invasion, necrosis, growth pattern, and immunostaining using whole-tumor sections and tissue microarrays. Hum Pathol 2005;36:994-1002.
32. Lopes JM, Bruland OS, Bjerkehagen B, Silva MC, Holm R, Pettersen EO, et al. Synovial sarcoma: immunohistochemical expression of Pglycoprotein and glutathione S transferase-pi and clinical drug resistance. Pathol Res Pract 1997;193:21-36.
33. McKay JA, Murray GI, Ewen SW, Melvin WT, Burke MD. Immunohistochemical localization of glutathione S-transferases in sarcomas. J Pathol 1994;174:83-7.
34. Komdeur R, Molenaar WM, Zwart N, Hoekstra HJ, van den Berg E, van der Graaf WT. Multidrug resistance proteins in primary and metastatic soft-tissue sarcomas: down-regulation of P-glycoprotein during metastatic progression. Anticancer Res 2004;24: 291-5.
35. Hipfner DR, Almquist KC, Stride BD, Deeley RG, Cole SP. Location of a protease-hypersensitive region in the multidrug resistance protein (MRP) by mapping of the epitope of MRP-specific monoclonal antibody QCRL-1. Cancer Res 1996;56:3307-14.
36. Stacchiotti S, Verderio P, Messina A, Morosi C, Collini P, Llombart-Bosch A, et al. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. Cancer 2012;118:5857-66.
37. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996;56:3010-20.
38. Rao VV, Anthony DC, Piwnica-Worms D. MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase. Cancer Res 1994;54:1536-41.
39. Breier A, Gibalova L, Seres M, Barancik M, Sulova Z. New insight into p-glycoprotein as a drug target. Anticancer Agents Med Chem 2013; 13:159-70.
40. Garrido W, Munoz M, San Martin R, Quezada C. FK506 confers chemosensitivity to anticancer drugs in glioblastoma multiforme cells by decreasing the expression of the multiple resistance-associated protein-1. Biochem Biophys Res Commun 2011;411:62-8.
41. Perez J, Bardin C, Rigal C, Anthony B, Rousseau R, Dutour A. Anti-MDR1 siRNA restores chemosensitivity in chemoresistant breast carcinoma and osteosarcoma cell lines. Anticancer Res 2011;31: 2813-20.
42. Bramwell VH, Morris D, Ernst DS, Hings I, Blackstein M, Venner PM, et al. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin Cancer Res 2002;8:383-93.
43. Susa M, Iyer AK, Ryu K, Choy E, Hornicek FJ, Mankin H, et al. Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One 2010;5:e10764.
44. Villar VH, Vogler O, Martinez-Serra J, Ramos R, Calabuig-Farinas S, Gutierrez A, et al. Nilotinib counteracts P-glycoproteinmediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas. PLoS One 2012;7: e37735.